

## Accepted Manuscript


Design considerations for nanotherapeutics in oncology

Triantafyllos Stylianopoulos, Rakesh K. Jain

PII: S1549-9634(15)00158-6  
DOI: doi: [10.1016/j.nano.2015.07.015](https://doi.org/10.1016/j.nano.2015.07.015)  
Reference: NANO 1166

To appear in: *Nanomedicine: Nanotechnology, Biology, and Medicine*

Received date: 27 May 2015  
Revised date: 20 July 2015  
Accepted date: 22 July 2015



Please cite this article as: Stylianopoulos Triantafyllos, Jain Rakesh K., Design considerations for nanotherapeutics in oncology, *Nanomedicine: Nanotechnology, Biology, and Medicine* (2015), doi: [10.1016/j.nano.2015.07.015](https://doi.org/10.1016/j.nano.2015.07.015)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Design considerations for nanotherapeutics in oncology

Triantafyllos Stylianopoulos<sup>1</sup> and Rakesh K. Jain<sup>2</sup>

<sup>1</sup>Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering,  
University of Cyprus, 1678, Nicosia, Cyprus

<sup>2</sup>Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General  
Hospital and Harvard Medical School, 02114, Boston, MA, USA

Corresponding authors:

Triantafyllos Stylianopoulos,

Tel: +357 2289.2238, Fax: +357 2289.5081, E-mail: [tstylian@ucy.ac.cy](mailto:tstylian@ucy.ac.cy)

Rakesh K. Jain

Tel: 617.726.4083, Fax: 617.724.1819, E-mail [jain@steele.mgh.harvard.edu](mailto:jain@steele.mgh.harvard.edu)

Conflict of interests: R.K.J. received research grants from Dyax, MedImmune and Roche; consulting fees from Enlight, Ophthotech, SPARC and SynDevRx; owns equity in Enlight, Ophthotech, SynDevRx and XTuit, serves on the Board of Directors of XTuit and Board of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. No reagents or funding from these companies was used in these studies. Therefore, there is no significant financial or other competing interest in the work.

This work was supported by the European Commission, Marie-Curie Reintegration grant (No. PIRG08-GA-2010-276894) to TS, the National Cancer Institute (P01-CA080124, R01-CA126642, R01-CA115767, R01-CA096915, R01-CA085140, R01-CA098706, Federal Share Income Grant), and a DoD Breast Cancer Research Innovator award (W81XWH-10-1-0016) to RKJ.

Abstract: 150 words, Main text: 6503 words (body text and figure captions), Number of references: 149, Number of Tables: 3, Number of figures: 4.

Download English Version:

<https://daneshyari.com/en/article/10436018>

Download Persian Version:

<https://daneshyari.com/article/10436018>

[Daneshyari.com](https://daneshyari.com)